In-laboratory removal of femoral sheath following protamine administration in patients having intracoronary stent implantation.
Two hundred twenty-eight patients with successful coronary stent implantation were randomized either to protamine administration and femoral sheath removal (group I, n = 117) or no heparin neutralization and delayed sheath removal (group II, n = 111). The hospital stay after treatment was shorter in patients receiving protamine; therefore, protamine use for neutralizing circulating heparin may be safely administered immediately after stent implantation.
Pan
M
M
Hospital Reina Sofía, University of Córdoba, Spain.
Suárez de Lezo
J
J
Medina
A
A
Romero
M
M
Hernández
E
E
Segura
J
J
Melian
F
F
Wangüemert
F
F
Landin
M
M
Benítez
F
F
Amat
M
M
Velasco
F
F
Torres
A
A
D000925:Anticoagulants / Q000627:therapeutic use; D003327:Coronary Disease / Q000628:therapy*; D017985:Dalteparin / Q000627:therapeutic use; D005260:Female; D005263:Femoral Artery; D006470:Hemorrhage / Q000517:prevention & control; D006493:Heparin / Q000627:therapeutic use; D006494:Heparin Antagonists / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011292:Premedication; D011479:Protamines / Q000627:therapeutic use*; D015607:Stents; D013927:Thrombosis / Q000517:prevention & control
D000925:Anticoagulants; D006494:Heparin Antagonists; D011479:Protamines; D006493:Heparin; D017985:Dalteparin